Founded in July 2013, Mifcare is a privately held biotechnology company headquartered in Paris, France.
Based on its proprietary medicinal chemistry technology, Mifcare designs and develops innovative orally-available small-molecule inhibitors of cytokine macrophage migration inhibitory factor (MIF), for the prevention and treatment of chronic inflammatory diseases with a primary focus on pulmonary arterial hypertension (PAH). Mifcare is commited to developing safe and effective drugs. We believe these commitments will enable us to bring to market innovative drugs that will benefit patients.
The strategy adopted by Mifcare is to forge partnerships with major players in the pharmaceutical or biotechnology industry to accelerate the development of its drug candidates.